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HenocheScho¨nlein Purpura (HSP), a non-granulomatous,
immunoglobulin A-mediated small vessels vasculitis. It is
the most common vasculitis in pediatric age group with an
incidence of 20 per 100,000 in children less than 17 years of
age with a peak incidence of 70 per 100,000 in children
between the ages of 4 and 6 years [1e5]. It presents with a
tetrad of palpable purpura, arthritis or arthralgia,entre (General Organization), Saudi Arabia. Production and hosting
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 2 Purpuric rash over upper and lower extremities.
Figure 3 Purpuric rash over upper and lower extremities.
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manifestations may vary from solely colicky abdominal pain
in about one-half of patients to GI bleeding in approxi-
mately 20e30 percent of patients [2,3]. However, rarely GI
complications including acute pancreatitis and bowel
perforation may occur [1]. A previous study by Prenzel have
reported an association between severe HSP and factor XIII
deficiency [5].
In this study, we report 3 cases of HSP with severe GI
manifestations in the form of melena, hematemesis, acute
pancreatitis, and erosive gastritis. All were unresponsive to
corticosteroids. Low levels of factor XIII were found in all
patients. Fortunately, they showed dramatic response to
Cryoprecipitate transfusion.
2. Case 1
An 11-year-old girl, previously healthy, admitted with his-
tory of skin rash, abdominal pain, and vomiting for 12 days.
The skin rash started at the lower extremities then pro-
gressed gradually to the buttocks area, upper extremities
and face. The abdominal pain was periumbilical, colicky in
nature, severe, and associated with vomiting. The vomiting
had been associated with streaks of blood. She was
admitted initially to a local hospital where she was treated
conservatively, but she had worsening symptoms with sig-
nificant abdominal distension and severe pain. She was
referred to our hospital for further workup and
management.
Physical examination upon arrival revealed ill-looking
girl, in pain, conscious, oriented, and well hydrated. Her
vitals were stable. She had purpuric rash over the face in a
malar distribution (Fig. 1), upper and lower extremities
with ulcerated lesions over both elbows and malleoli (Figs.
2e4). She had a distended abdomen with generalized
tenderness, more in the epigastric and umbilical regions.
Other examinations were unremarkable.
Laboratory data revealed: high white blood cell count at
22  109/L (normal 5e15) with predominant neutrophils
(79%), low hemoglobin 10.4 mg/dl (normal 11e14), high
platelet count 358  109/L (normal 140e350), normal
erythrocyte sedimentation rate (ESR) at 2 mm/hr, high C-
reactive protein (CRP) at 39.8 mg/L (normal > 3), normal
renal functions and electrolytes, high amylase at 275 U/L
(normal range 3e110), high lipase at 584 IU/L (normal
range 0e60), and normal complements levels. Antinuclear
antibodies, anti-SSB, anti-SSA, prothrombin time (PT),
partial thromboplastin time (PTT), international normal-
ized ratio (INR), occult blood in stool and urinalysis were
negative.Figure 1 Purpuric rash in a malar distribution.Abdominal radiograph showed evidence of paralytic
ileus with multiple air-fluid levels suggestive of intestinal
obstruction. Abdominal ultrasound reported moderate,
free intraperitoneal fluid with inability to visualize the
pancreas due to marked bowel gas shadowing. Abdominal
computerized tomography (CT) showed diffuse swollen
edematous pancreas, which confirmed the diagnosis of
pancreatitis.
She was started on daily intravenous (IV) methylpred-
nisolone pulse (30 mg/kg/dose) for 3 days without signifi-
cant improvement. She was kept NPO (null per oral), on
nasogastric tube (NGT) suctioning and analgesia. Skin bi-
opsy showed leukocytoclastic vasculitis with IgA deposition
confirming the diagnosis of HSP (Fig. 5). A week later, she
developed melena; hence, upper endoscopy was performed
and showed evidence of severe erosive gastritis with
normal esophagus and duodenum. Therefore, NGT suc-
tioning was continued and IV omeprazole and total parental
nutrition (TPN) were started. IV methylprednisolone and IV
immunoglobulin (IVIG) were administered, but it was
without any significant improvement. Assay of Factor XIII
showed low level at 0.3 IU/ml (normal range 0.7e1.2 IU/
ml). Subsequently, Cryoprecipitate transfusion (60 ml
equivalent to 3 units) was given 2 weeks after admission (onFigure 4 Purpuric rash over upper and lower extremities.
Figure 5 Leukocytoclastic vasculitis with IgA deposition.
86 A. Al Sonbul et al.day 11 after methylprednisolone and IVIG treatment), and
the patient had dramatic improvement; her abdominal pain
subsided and the rash lessened. The transfusion was well
tolerated with adverse occurrences. Her oral intake
improved and TPN was stopped. She became asymptomatic
and was discharged in a stable condition.
3. Case II
A 3-year-old previously healthy girl presented one month
prior to her admission with purpuric rash which started on
her feet then progressed proximally to involve lower limbs,
upper limbs, trunk, buttocks, and face. Simultaneously, she
complained from mild abdominal pain, so she was diag-
nosed as HSP. Two days later, she had severe abdominal
pain followed by vomiting, hematemesis, and melena.
Methylprednisolone pulse (30 mg/kg/day) was given for 3
days followed by oral prednisolone 1 mg/kg/day for 8 days
with partial improvement. She was then referred to our
hospital for further management.
Upon arrival to our hospital, she had recurrent abdom-
inal pain, vomiting, and rash reappeared on face, ears,
trunk, lower, and upper extremities. However, there was no
more hematemesis or melena. Investigations revealed
normal complete blood counts, ESR, CRP, renal, and he-
patic profiles. Urinalysis was negative for blood or protein.
Abdominal radiograph showed fecal loading up to the
cecum. Ultrasound abdomen was normal. Skin biopsy was
consistent with leukocytoclastic vasculitis, and immuno-
fluorescence was positive for fibrinogen in blood vessels,
but it was negative for complements C3, C1q, immuno-
globulin G, A, and M. Factor XIII assay showed low level at
0.39 IU/ml so Cryoprecipitate transfusion (40 ml equivalent
to 2 units) was given (on day 16 after methylprednisolone
treatment) with marked improvement of abdominal pain,
vomiting, and rash. There were no complications encoun-
tered during or after transfusion.
4. Case III
A previously healthy 4-year-old boy presented 3 weeks prior
to admission with periumbilical abdominal pain. It was
intermittent, colicky, severe enough to interfere with dailyactivities, and associated with vomiting. On the same day,
he developed purpuric skin rash on lower limbs and but-
tocks. He was admitted twice due to recurrent abdominal
pain and treated conservatively in the local hospital. In the
third admission, he received steroid 15 mg/kg/day intra-
venously followed by maintenance on 1 mg/kg/day in
divided doses with no significant response. Subsequently,
he was referred to our hospital for further management.
Examinations showed a well-looking boy, normotensive,
has scattered purpuric rash mainly over both elbows with
fewer lesions on upper and lower extremities. His initial
abdominal examination was reassuring, but he continued to
have bouts of colicky severe abdominal pain associated
with vomiting. His workup showed leukocytosis at
16.75  109/L with 82% neutrophils but normal hemoglobin,
platelets, and inflammatory markers. Coagulation profile,
lipase level, renal function, and hepatic profile were within
normal ranges. Stool was positive for occult blood on more
than one occasion. Abdominal X-ray showed moderate fecal
loading, and abdominal ultrasonography showed normal
viscera apart from fatty liver with no organomegaly and
stool distended large bowel compatible with constipation.
On the 4th day of admission, he developed a severe attack
of abdominal pain associated with recurrent vomiting,
hematemesis, and melena. An urgent ultrasound ruled out
the presence of intestinal intussusception, and it only
showed distended large bowel. Repeated CBC showed
leukocytosis up to 26.75  109/L with 67% neutrophils,
elevated CRP at 15.7 mg/L and normal ESR at 3 mm/Hr.
Methylprednisolone pulse (10 mg/kg/day) was given for 2
days after the GI bleeding with no major effect. Factor XIII
level was low at 0.58 IU/ml. Cryoprecipitate transfusion
(60 ml equivalent to 3 units) was given 4 days after meth-
ylprednisolone pulses which shortly resulted in a significant
improvement. However, the patient required a repeat
transfusion of 3 extra units after which his symptoms
completely resolved with no transfusion complications.
5. Discussion
HSP is the most common childhood vasculitis which has
usually self-limited course with excellent prognosis. Pur-
pura occurs in all cases, joint pains and arthritis in 80%, and
abdominal pain in 62%. Some include gastrointestinal
hemorrhage as a fourth criterion; this occurs in 33% of
cases, sometimes, but not necessarily always, due to
intussusception [6]. Severe clinical manifestations,
including gastrointestinal, can be seen either at presenta-
tion or during the disease course. Intestinal bleeding and
obstruction or intussusceptions can complicate the disease
course [6]. Acute Pancreatitis was reported in a 3-year-old
girl who presented with abdominal pain then developed
characteristic rash of HSP at the fifth day of clinical onset
[7]. A correlation between reduced plasma factor XIII ac-
tivity, and the severity of multiple organ disorders, espe-
cially abdominal symptoms, has been shown in pediatric
HSP in previous case studies [8].
In our series, we report 3 children with typical HSP but
severe GI manifestations including severe abdominal pain,
hematemesis, melena in all patients, in addition to
pancreatitis, and erosive gastritis in the first patient. High
Cryoprecipitate Successful treatment of HSP severe gastrointestinal manifestations 87dose steroid pulses or oral prednisone as well as IVIG in the
first patient did not help in alleviating the symptoms. All
the three patients had low levels of factor XIII during their
presentation then dramatic improvement within few hours
following Cryoprecipitate transfusion which contain factor
XIII.
Factor XIII (FXIII) is the last enzyme in the clotting
cascade. Its main function is to convert the loose fibrin
polymer into a firm, highly organized, cross-linked struc-
ture with increased tensile strength, firmly anchored to the
site of the wound and possessing an in-built resistance to
fibrinolysis. In factor XIII deficiency, standard clotting tests
are normal, as the clotting end point is not affected by the
absence of factor XIII [9]. All our patients had normal basic
coagulation profile including PT, PTT, and INR despite sig-
nificant hemorrhagic gastrointestinal symptoms.
Acquired factor XIII deficiency, when the level drops to
20e70% [10], remains a doubtful entity. Low plasma levels
of factor XIII activity have been reported in some conditions
like inflammatory bowel disease, systemic lupus erythe-
matosus, and rheumatoid arthritis which are characterized
by the presence of autoantibodies [11e13]. Whether the
low factor XIII levels contribute to hemorrhagic complica-
tions in these diseases remains to be proven. Factor XIII
deficiency might result into life-threatening bleeding.
Massive intracerebral hemorrhage [14] and compartment
syndrome of the forearm due to hemorrhage [15] were re-
ported in two children with HSP and severe deficiency of
factor XIII. Treatment of patients bleeding from the small
bowel in HSP and from the large bowel in ulcerative colitis
with factor XIII concentrate has been reported to be
effective in controlling the bleeding [16]. The benefits of
such therapy remain unconfirmed and factor XIII therapy in
these circumstances cannot be recommended until more
scientific evidence emerges in support of such an approach,
and the possible mechanisms of factor XIII action in these
situations elucidated.
In our reported cases, the first patient has the lowest
level of factor XIII (0.3 IU/ml) and the most severe purpuric
rash and gastrointestinal manifestations in form of acute
pancreatitis and erosive gastritis, in addition to severe
abdominal pain, hematemesis, and melena which were
seen in the two other patients.
All our patients showed remarkable improvement of
their gastrointestinal symptoms shortly after the trans-
fusion of Cryoprecipitate. The amount transfused was one
unit per 10 kg of body weight as per the blood products
transfusion guidelines of our blood bank. Cryoprecipitate
contains fibrinogen, factor VIII, von Willbrand factor, factor
XIII, and fibonectin. Factor XIII substitution therapy using a
fibrinogen preparation containing abundant factor XIII with
an antiplasmin agent resulted in improvement of severe
gastrointestinal hemorrhage in 13 out of 17 HSP affected
children [17]. As well, other studies showed that adminis-
tration of factor XIII in a group of moderate HSP showed
remarkable improvement of joint symptoms and renal
dysfunction in addition to gastrointestinal symptoms [18]. It
is worth mentioning that all our patients had no significant
renal or articular involvement despite the severe GI symp-
toms and widespread purpura.
Prenzel et al supported the hypothesis that factor XIII
activity correlates well with the severity of abdominalsymptoms. There was no improvement after treatment
with prednisone and symptoms resolved after factor XIII
concentrate administration. Matayoshi et al showed that
there was no correlation between factor XIII activities and
the distribution of purpura, which in turn, was not corre-
lated with the severity of organ disorders in adult patients
[19]. Few studies have reported a correlation between the
severity of HSP and factor XIII deficiency. Hogendorf et al
showed improvement of factor XIII and symptoms resolution
in 2 affected children without any intervention [20]. A case
series of 3 children with HSP and isolated gastrointestinal
symptoms described a reduction in factor XIII activity prior
to the development of skin rash without the need for sub-
stitution treatment [21].
There is no literature differentiating the pathophysio-
logical effects of cryoprecipitate, and it remains unclear if
cryoprecipitate modify the inflammatory or thrombotic
processes in such disease or similar vasculitic or inflam-
matory diseases.
Our study main limitation is the small number of pa-
tients, and the retrospective study type. Standardization of
such therapy regarding treatment regimen and dosage
needs to be tested in larger prospective studies.
In conclusion, Severe HSP manifestations particularly
those related to GI symptoms like life-threatening GI
bleeding might be associated with an acquired factor XIII
deficiency. Factor XIII assay should be routinely measured
in any patient with severe HSP since the replacement
treatment of such temporarily deficient factor is curative.
Cryoprecipitate should be an excellent alternative if factor
XIII concentrate is not available.Conflict of interest
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